H. de Voogt

发表

Retrospective study of prognostic importance of DNA flow cytometry of urinary bladder carcinoma.

J. Baak, N. Schipper, C. Blomjous, 1988, Journal of clinical pathology.

Cytological changes due to urinary calculi: a consideration of the relationship between calculi and the development of urothelial carcinoma.

J. A. Brussee, L. Cuypers, M. E. Beyer-Boon, 1978, British journal of urology.

Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer

J. Klijn, F. Schröder, R. Sylvester, 1998, European Urology.

Renewal timing of long‐acting depot luteinizing hormone‐releasing hormone agonist (Zoladex) is critical in the treatment of hormone‐dependent rat prostatic carcinoma (R3327‐H)

A. Geldof, H. de Voogt, B. Rao, 1987, The Prostate.

Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate

A. Geldof, L. Gooren, L. Gooren, 1988, The Prostate.

Assessment of quality of life and subjective response criteria in patients with prostatic cancer.

S. Fosså, N. Aaronson, F. D. da Silva, 1990, Progress in clinical and biological research.

Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.

J. Klijn, F. Debruyne, F. de Jong, 1987, The Journal of urology.

Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.

R. Sylvester, M. Pavone-Macaluso, S. Suciu, 1989, The Journal of urology.

Update of EORTC clinical trials in prostate cancer. The EORTC Genito-Urinary Group.

R. Sylvester, L. Denis, D. Newling, 1992, Seminars in urology.

The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials

R. Sylvester, L. Denis, H. de Voogt, 1998, European Urology.

Merits and considerations in the use of anti-androgen.

A. Geldof, L. Gooren, H. de Voogt, 1988, Journal of steroid biochemistry.

Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer

A. Geldof, C. L. van der Wilt, H. de Voogt, 1988, The Prostate.

Subjective response criteria and quality of life.

N. Aaronson, H. de Voogt, F. Calais da Silva, 1988, Progress in clinical and biological research.

The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents.

H. de Voogt, H. Adenauer, W. Widdra, 1991, Scandinavian journal of urology and nephrology. Supplementum.

The effects of cyclophosphamide treatment on the epithelium and stroma of the urinary bladder.

A. Schaberg, M. E. Beyer-Boon, H. J. Voogt, 1978, European journal of cancer.

The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma.

J. Baak, C. Meijer, N. Schipper, 1989, American journal of clinical pathology.

Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases

C. Meijer, P. Valk, H. J. Voogt, 1989, Cancer.

Morphometric and flow cytometric analysis of small cell undifferentiated carcinoma of the bladder.

J. Baak, C. Meijer, N. Schipper, 1989, Journal of clinical pathology.

The prognostic significance of selective nuclear morphometry in urinary bladder carcinoma.

J. Baak, C. Meijer, N. Schipper, 1990, Human pathology.

Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.

S. Suciu, M. de Pauw, H. de Voogt, 1986, The Journal of urology.

Experiences with the ureterocolonic anastomosis after Mathisen.

H. de Voogt, N. Bakker, D. Tjabbes, 1970, The Journal of urology.

Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.

R. Sylvester, B. Lardennois, M. de Pauw, 1986, The Journal of urology.

The position of cyproterone acetate (CPA), a steroidal anti‐androgen, in the treatment of prostate cancer

H. de Voogt, 1992, The Prostate. Supplement.

Short‐term versus long‐term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer

J. Klijn, R. Sylvester, U. Studer, 1993, Cancer.

EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.

R. Sylvester, S. Suciu, B. Lardennois, 1989, Progress in clinical and biological research.

Present concept of the relevance of steroid receptors for prostatic cancer.

H. de Voogt, B. Rao, 1983, Journal of Steroid Biochemistry.

Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.

S. Suciu, M. de Pauw, H. de Voogt, 1988, Progress in clinical and biological research.

Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.

J. Klijn, F. Debruyne, F. de Jong, 1985, Progress in clinical and biological research.

Preliminary results with iodine-125 seeds for permanent implantation in patients with localized prostatic cancer.

J. Battermann, T. Boon, H. de Voogt, 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cytology of Bladder Tumours — Round Table

P. Esposti, H. J. Voogt, H. de Voogt, 1980 .

Clinical aspects of urinary cytology.

G. Wielenga, H. de Voogt, 1972, Acta cytologica.